Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

• Status: Completed
• Trial end date: 2019-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether RPC1063 is effective in the treatment of ulcerative colitis (UC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene
• Treatments: Ozanimod

Criteria

Inclusion Criteria:

• Ulcerative colitis (UC) confirmed on endoscopy

• Moderately to severely active UC (Mayo score 6-12)

Exclusion Criteria:

• Current use of anti-TNF agents